Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

9.3K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.3K
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

10.4K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.4K
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

3.4K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

6.5K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antibiotics promote susceptibility to <i>C. difficile</i> infection through a CCR5-dependent immune response.

bioRxiv : the preprint server for biology·2026
Same author

Wolf in sheep's clothing: leveraging sheep to study how maternal immune activation contributes to neurodevelopmental disorders.

Brain, behavior, and immunity·2026
Same author

Microglial CLEC7A restrains amyloid beta plaque pathology in a mouse model of Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Taking the STING out of neurodegenerative disease.

The Journal of experimental medicine·2025
Same author

Peripheral infection wires T cells in the brain.

Nature immunology·2025
Same author

STING deletion protects against amyloid β-induced Alzheimer's disease pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Related Experiment Video

Updated: Apr 14, 2026

Author Spotlight: Understanding the Impact of Pathological Proteins on Axonal Transport in Neurodegenerative Diseases
10:38

Author Spotlight: Understanding the Impact of Pathological Proteins on Axonal Transport in Neurodegenerative Diseases

Published on: December 22, 2023

1.2K

The Genotoxic Stress Sensor ZBP1 Drives Tau Pathology.

Jessica M Thanos1, Olivia C Campbell1, Nick R Natale1,2,3

  • 1Center for Brain Immunology and Glia (BIG), Harrison Family Translational Research Center in Alzheimer's and Neurodegenerative Diseases, Department of Neuroscience, University of Virginia, Charlottesville, VA 22908, USA.

Cells
|April 13, 2026
PubMed
Summary

Genotoxic stress sensor Z-DNA binding protein 1 (ZBP1) drives neuroinflammation and neuronal loss in tauopathy. Deleting ZBP1 protected against tau pathology and neuronal damage, suggesting ZBP1 as a therapeutic target.

Keywords:
Alzheimer’s diseaseZBP1genotoxic stressinnate immunologyneurodegenerative diseaseneuroinflammationnucleic acid sensingtauopathy

More Related Videos

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

19.1K
Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

7.5K

Related Experiment Videos

Last Updated: Apr 14, 2026

Author Spotlight: Understanding the Impact of Pathological Proteins on Axonal Transport in Neurodegenerative Diseases
10:38

Author Spotlight: Understanding the Impact of Pathological Proteins on Axonal Transport in Neurodegenerative Diseases

Published on: December 22, 2023

1.2K
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

19.1K
Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

7.5K

Area of Science:

  • Neuroscience
  • Immunology
  • Genetics

Background:

  • Genotoxic stress and neuroinflammation are hallmarks of neurodegenerative diseases like Alzheimer's.
  • Innate immune sensors detecting DNA damage are increasingly implicated in neurodegeneration.
  • Z-DNA binding protein 1 (ZBP1) is a newly identified sensor of Z-DNA and Z-RNA, linked to cell death and inflammation.

Purpose of the Study:

  • To investigate the role of ZBP1 in the pathogenesis of tauopathy.
  • To determine if ZBP1 deletion offers protection in a mouse model of tau-mediated neurodegeneration.

Main Methods:

  • Utilized the PS19 mouse model of tauopathy.
  • Assessed the impact of ZBP1 deletion on tau pathology, neuronal loss, and glial activation (microglia and astrocytes).

Main Results:

  • ZBP1 deletion significantly protected against tau pathology and neuronal loss in the PS19 mouse model.
  • Ablation of ZBP1 led to reduced activation of microglia and astrocytes, indicating dampened neuroinflammation.
  • ZBP1 was identified as a key sensor driving tau pathology and associated neurodegeneration.

Conclusions:

  • ZBP1 plays a critical role in mediating tau pathology, gliosis, and neuronal death in tauopathy.
  • Targeting ZBP1 presents a potential therapeutic strategy for treating tau-mediated neurodegenerative diseases.